Global Markets for Alzheimer's Disease Medications : Market Research Report

Global Markets for Alzheimer's Disease Medications

Published: Apr. 1, 2005

EXECUTIVE SUMMARY
METHODOLOGY
1.0 AD OVERVIEW
1.1 Definition of AD: 1.1.1 Symptoms; 1.1.2 Diagnosis
1.2 Segmentation of AD
1.3 Prevalence of AD
1.4 Unmet Needs in AD
1.5 Market Analyses Assumptions: 1.5.1 Generic Competition; 1.5.2 UK Forecasts; 1.5.3 Mild to Moderate Market Assumptions; 1.5.4 Moderate to Severe Market Assumptions
1.6 Market Analysis: 1.6.1 US Market Forecast; 1.6.2 European Market Forecast; 1.6.3 Japanese Market Forecast
1.7 Competitive Analysis
1.8 Drugs That Address Associated Conditions
1.9 AD Research and Development: 1.9.1 ACh Modulators; 1.9.2 Neuroprotective and Neurotrophic Drugs; 1.9.3 Beta-Amyloid Modulators; 1.9.4 Beta-Secretase Inhibitors; 1.9.5 Other Compounds Under Development for AD; 1.9.6 Application of Existing Products to AD; 1.9.7 Innovative Approaches
2.0 AD PATIENT POPULATION
2.1 Definition of AD: 2.1.1 Epidemiology; 2.1.2 Symptoms; 2.1.3 Diagnosis
2.2 Segmentation of AD: 2.2.1 Mild to Moderate Forms of AD; 2.2.2 Moderate to Severe Forms of AD
2.3 AD Prevalence: 2.3.1 Mild to Moderate AD Prevalence; 2.3.2 Moderate to Severe AD Prevalence
2.4 Treated AD Patients
2.5 Average Selling Prices
2.6 Unmet Needs in Diagnosis and Treatment of AD: 2.6.1 Unmet Needs in the Diagnosis and Treatment of AD in the US; 2.6.2 Unmet Needs in the Diagnosis and Treatment of AD in Europe; 2.6.3 Unmet Needs in the Diagnosis and Treatment of AD in Japan
3.0 MILD TO MODERATE AD MARKET
3.1 Market Overview
3.2 Mild to Moderate AD Drugs: 3.2.1 Cognex; 3.2.2 Aricept (Memac); 3.2.3 Exelon (Prometax); 3.2.4 Reminyl
3.3 Market Analysis: 3.3.1 US Market Forecast; 3.3.2 European Market Forecast; 3.3.3 Japanese Market Forecast
3.4 Competitive Analysis
4.0 MODERATE TO SEVERE AD MARKET
4.1 Market Overview
4.2 Moderate to Severe AD Drugs: 4.2.1 Namenda; 4.2.2 Axura; 4.2.3 Ebixa
4.3 Market Analysis: 4.3.1 US Market Forecast; 4.3.2 European Market Forecast; 4.3.3 Japanese Market Forecast
4.4 Competitive Analysis
5.0 RESEARCH AND DEVELOPMENT
5.1 AD Research Overview: 5.1.1 ACh Modulators; 5.1.2 Neuroprotective and Neurotrophic Drugs; 5.1.3 Beta-Amyloid Modulators; 5.1.4 Beta-Secretase Inhibitors; 5.1.5 Other Drugs Under Development for AD; 5.1.6 Application of Existing Products to AD; 5.1.7 Innovative Approaches
5.2 Companies Involved in AD Research: 5.2.1 Eli Lilly; 5.2.2 Pfizer/Eisai; 5.2.3 Sanofi-Aventis; 5.2.4 Axonyx; 5.2.5 Nymox; 5.2.6 Prana Biotechnology; 5.2.7 Neurochem; 5.3 Discontinued Development Projects; 5.3.1 ProMem — Bayer; 5.3.2 Viviq — Aventis
APPENDIX A: MRG ACRONYMS AND INITIALISMS
List of Exhibits
EXECUTIVE SUMMARY
Exhibit ES-1: AD Drug Market, by Region, Global, (US$), 2003-2009
Exhibit ES-2: AD Prevalence Rates, by Region and Disease Stage, Global, 2004. ES-3
Exhibit ES-3: Treated AD Patients, by Region, Global, 2003-2009
Exhibit ES-4: ASP per Patient, by Region, Global, (US$), 2003-2009
Exhibit ES-5: Mild to Moderate AD Drug Market, by Brand, Global, (US$), 2003-2009
Exhibit ES-6: Memantine Marketing Rights, by Region, Brand, and Company, Global, 2004
Exhibit ES-7: Moderate to Severe AD Drug Market, as a % of Total, by Region, Europe, 2004 versus 2009
Exhibit ES-8: Leading Competitors in the AD Drug Market, Global, 2004
CHAPTER 1: AD OVERVIEW
Exhibit 1-1: AD Prevalence Rates, by Region and Disease Stage, Global, 2004
Exhibit 1-2: Availability of AD Drug Medications, by Region Global, Q1 2005
Exhibit 1-3: AD Drug Market, by Region, Global, (US$), 2003-2009 (Tabular Format)
Exhibit 1-4: AD Drug Market, by Region, Global, (US$), 2003-2009 (Graphical Format)
Exhibit 1-5: AD Drug Market, by Brand, Global, (US$), 2003-2009 (Tabular Format)
Exhibit 1-6: AD Drug Market, by Brand, Global, (US$), 2003-2009 (Graphical Format)
Exhibit 1-7: AD Drug Market, by Brand, US, (US$), 2003-2009 (Tabular Format)
Exhibit 1-8: AD Drug Market, by Brand, US, (US$), 2003-2009 (Graphical Format)
Exhibit 1-9: AD Drug Market, by Region, Europe, (US$), 2003-2009
Exhibit 1-10: AD Drug Market, by Region, Europe, (€), 2003-2009
Exhibit 1-11: AD Drug Market, by Region, as a % of Total, Europe, 2003-2009 (Tabular Format)
Exhibit 1-12: AD Drug Market, by Region, as a % of Total, Europe, 2003-2009 (Graphical Format)
Exhibit 1-13: AD Drug Market, by Brand, Europe, (US$), 2003-2009 (Tabular Format)
Exhibit 1-14: AD Drug Market, by Brand, Europe, (€), 2003-2009
Exhibit 1-15: AD Drug Market, by Brand, Europe, (US$), 2003-2009 (Graphical Format)
Exhibit 1-16: AD Drug Market, by Brand, France, (US$), 2003-2009
Exhibit 1-17: AD Drug Market, by Brand, France, (€), 2003-2009
Exhibit 1-18: AD Drug Market, by Brand, Germany, (US$), 2003-2009
Exhibit 1-19: AD Drug Market, by Brand, Germany, (€), 2003-2009
Exhibit 1-20: AD Drug Market, by Brand, UK, (US$), 2003-2009
Exhibit 1-21: AD Drug Market, by Brand, UK, (€), 2003-2009
Exhibit 1-22: AD Drug Market, by Brand, UK, (£), 2003-2009
Exhibit 1-23: AD Drug Market, by Brand, Italy, (US$), 2003-2009
Exhibit 1-24: AD Drug Market, by Brand, Italy, (€), 2003-2009
Exhibit 1-25: AD Drug Market, by Brand, Spain, (US$), 2003-2009
Exhibit 1-26: AD Drug Market, by Brand, Spain, (€), 2003-2009
Exhibit 1-27: AD Drug Market, by Brand, Japan, (US$), 2003-2009 (Tabular Format)
Exhibit 1-28: AD Drug Market, by Brand, Japan, (¥), 2003-2009
Exhibit 1-29: AD Drug Market, by Brand, Japan, (US$), 2003-2009 (Graphical Format)
Exhibit 1-30: Leading Competitors in the AD Drug Market, by Region, Global, 2004
Exhibit 1-31: Leading Competitors in the AD Drug Market, Global, 2004
Exhibit 1-32: Leading Competitors in the AD Drug Market, by Region, Europe, 2004
Exhibit 1-33: Leading Competitors in the AD Drug Market, Europe, 2004
Exhibit 1-34: Leading Competitors in the AD Drug Market, Market Value and Market Shares, (US$), Global, 2004
Exhibit 1-35: Leading Competitors in the AD Drug Market, Market Value and Market Shares, (US$), US, 2004
Exhibit 1-36: Leading Competitors in the AD Drug Market, Market Value and Market Shares, Europe, 2004
Exhibit 1-37: Leading Competitors in the AD Drug Market, Market Value and Market Shares, France, 2004
Exhibit 1-38: Leading Competitors in the AD Drug Market, Market Value and Market Shares, Germany, 2004
Exhibit 1-39: Leading Competitors in the AD Drug Market, Market Value and Market Shares, UK, 2004
Exhibit 1-40: Leading Competitors in the AD Drug Market, Market Value and Market Shares, Italy, 2004
Exhibit 1-41: Leading Competitors in the AD Drug Market, Market Value and Market Shares, Spain, 2004
CHAPTER 2: AD PATIENT POPULATION
Exhibit 2-1: GDS AD Classification Framework
Exhibit 2-2: AD Prevalence, by Region and Disease Stage, Global, 2004 (Tabular Format)
Exhibit 2-3: AD Prevalence, by Region and Disease Stage, Global, 2004 (Graphical Format)
Exhibit 2-4: AD Prevalence Rates, by Region, Global, 2004
Exhibit 2-5: AD Prevalence, by Region, Global, 2003-2009 (Tabular Format)
Exhibit 2-6: AD Prevalence, by Region, Global, 2003-2009 (Graphical Format)
Exhibit 2-7: AD Prevalence, by Region, Europe, 2003-2009 (Tabular Format)
Exhibit 2-8: AD Prevalence, by Region, Europe, 2003-2009 (Graphical Format)
Exhibit 2-9: Mild to Moderate AD Prevalence, by Region, Global, 2003-2009 (Tabular Format)
Exhibit 2-10: Mild to Moderate AD Prevalence, by Region, Global, 2003-2009 (Graphical Format)
Exhibit 2-11: Mild to Moderate AD Prevalence, by Region, Europe, 2003-2009 (Tabular Format)
Exhibit 2-12: Mild to Moderate AD Prevalence, by Region, Europe, 2003-2009 (Graphical Format)
Exhibit 2-13: Moderate to Severe AD Prevalence, by Region, Global, 2003-2009 (Tabular Format)
Exhibit 2-14: Moderate to Severe AD Prevalence, by Region, Global, 2003-2009 (Graphical Format)
Exhibit 2-15: Moderate to Severe AD, by Region, Europe, 2003-2009 (Tabular Format)
Exhibit 2-16: Moderate to Severe AD, by Region, Europe, 2003-2009 (Graphical Format)
Exhibit 2-17: AD Treatment Rates, as % of AD Prevalence, by Region, Global, 2003-2009
Exhibit 2-18: Treated AD Patients, by Region, Global, 2003-2009 (Tabular Format)
Exhibit 2-19: Treated AD Patients, by Region, Global, 2003-2009 (Graphical Format)
Exhibit 2-20: Treated AD Patients, by Region, Europe, 2003-2009 (Tabular Format)
Exhibit 2-21: Treated AD Patients, by Region, Europe, 2003-2009 (Graphical Format)
Exhibit 2-22: ASP per Patient, by Region, Global, (US$), 2003-2009 (Tabular Format)
Exhibit 2-23: ASP per Patient, by Region, Global, (Local Currencies), 2003-2009
Exhibit 2-24: ASP per Patient, by Region, Global, (US$), 2003-2009 (Graphical Format)
Exhibit 2-25: ASP per Patient, by Region, Europe, (US$), 2004
CHAPTER 3: MILD TO MODERATE AD MARKET
Exhibit 3-1: Mild to Moderate AD Drug Market, Global, (US$), 2003-2009
Exhibit 3-2: Availability of Mild to Moderate AD Drugs, by Brand, Global, 2004
Exhibit 3-3: Selected New Mild to Moderate AD Medications, Global, 2003-2009
Exhibit 3-4: Mild to Moderate AD Drug Market, by Region, Global, (US$), 2003-2009 (Tabular Format)
Exhibit 3-5: Mild to Moderate AD Drug Market, by Region, Global, (US$), 2003-2009 (Graphical Format)
Exhibit 3-6: Mild to Moderate AD Drug Market, by Brand, Global, (US$), 2003-2009 (Tabular Format)
Exhibit 3-7: Mild to Moderate AD Drug Market, by Brand, Global, (US$), 2003-2009 (Graphical Format)
Exhibit 3-8: Mild to Moderate AD Drug Market, by Brand, US, (US$), 2003-2009 (Tabular Format)
Exhibit 3-9: Mild to Moderate AD Drug Market, by Brand, US, (US$), 2003-2009 (Graphical Format)
Exhibit 3-10: Mild to Moderate AD Drug Market, by Region, Europe, (US$), 2003-2009
Exhibit 3-11: Mild to Moderate AD Drug Market, by Region, Europe, (€), 2003-2009
Exhibit 3-12: Mild to Moderate AD Drug Market, by Region, as a % of Total, Europe, 2003-2009
Exhibit 3-13: Mild to Moderate AD Drug Market, by Region, as a % of Total, Europe, 2004
Exhibit 3-14: Mild to Moderate AD Drug Market, by Brand, Europe, (US$), 2003-2009 (Tabular Format)
Exhibit 3-15: Mild to Moderate AD Drug Market, by Brand, Europe, (€), 2003-2009
Exhibit 3-16: Mild to Moderate AD Drug Market, by Brand, Europe, (US$), 2003-2009 (Graphical Format)
Exhibit 3-17: Mild to Moderate AD Drug Market, by Brand, France, (US$), 2003-2009
Exhibit 3-18: Mild to Moderate AD Drug Market, by Brand, France, (€), 2003-2009
Exhibit 3-19: Mild to Moderate AD Drug Market, by Brand, Germany, (US$), 2003-2009
Exhibit 3-20: Mild to Moderate AD Drug Market, by Brand, Germany, (€), 2003-2009
Exhibit 3-21: Mild to Moderate AD Drug Market, by Brand, UK, (US$), 2003-2009
Exhibit 3-22: Mild to Moderate AD Drug Market, by Brand, UK, (€), 2003-2009
Exhibit 3-23: Mild to Moderate AD Drug Market, by Brand, UK, (£), 2003-2009
Exhibit 3-24: Mild to Moderate AD Drug Market, by Brand, Italy, (US$), 2003-2009
Exhibit 3-25: Mild to Moderate AD Drug Market, by Brand, Italy, (€), 2003-2009
Exhibit 3-26: Mild to Moderate AD Drug Market, by Brand, Spain, (US$), 2003-2009
Exhibit 3-27: Mild to Moderate AD Drug Market, by Brand, Spain, (€), 2003-2009
Exhibit 3-28: Mild to Moderate AD Drug Market, by Brand, Japan, (US$), 2003-2009 (Tabular Format)
Exhibit 3-29: Mild to Moderate AD Drug Market, by Brand, Japan, (¥), 2003-2009
Exhibit 3-30: Mild to Moderate AD Drug Market, by Brand, Japan, (US$), 2003-2009 (Graphical Format)
Exhibit 3-31: Leading Competitors in the Mild to Moderate AD Drug Market, by Region, Global, 2004
Exhibit 3-32: Leading Competitors in the Mild to Moderate AD Drug Market, Global, 2004
Exhibit 3-33: Leading Competitors in the Mild to Moderate AD Drug Market, by Region, Europe, 2004
Exhibit 3-34: Leading Competitors in the Mild to Moderate AD Drug Market, Europe, 2004
CHAPTER 4: MODERATE TO SEVERE AD MARKET
Exhibit 4-1: Moderate to Severe AD Drug Market, by Region, Global, (US$), 2003-2009 (Graphical Format)
Exhibit 4-2: Memantine Marketing Rights, by Region, Brand, and Company, Global, 2004
Exhibit 4-3: Anticipated Medications for Treatment of Moderate to Severe AD, Global, 2003-2009
Exhibit 4-4: Moderate to Severe AD Drug Market, by Region, Global, (US$), 2003-2009 (Tabular Format)
Exhibit 4-5: Moderate to Severe AD Drug Market, by Brand, Global, (US$), 2003-2009
Exhibit 4-6: Moderate to Severe AD Drug Market, by Brand, as a % of Total, Global, 2004 versus 2009
Exhibit 4-7: Moderate to Severe AD Drug Market, by Brand, US, (US$), 2003-2009 (Tabular Format)
Exhibit 4-8: Moderate to Severe AD Drug Market, by Brand, US, (US$), 2003-2009 (Graphical Format)
Exhibit 4-9: Moderate to Severe AD Drug Market, by Region, Europe, (US$), 2003-2009
Exhibit 4-10: Moderate to Severe AD Drug Market, by Region, Europe, (€), 2003-2009
Exhibit 4-11: Moderate to Severe AD Drug Market, by Region, as a % of Total, Europe, 2003-2009 (Tabular Format)
Exhibit 4-12: Moderate to Severe AD Drug Market, by Region, as a % of Total, Europe, 2003-2009 (Graphical Format)
Exhibit 4-13: Moderate to Severe AD Drug Market, by Brand, Europe, (US$), 2003-2009 (Tabular Format)
Exhibit 4-14: Moderate to Severe AD Drug Market, by Brand, Europe, (€), 2003-2009
Exhibit 4-15: Moderate to Severe AD Drug Market, by Brand, Europe, (US$), 2003-2009 (Graphical Format)
Exhibit 4-16: Moderate to Severe AD Drug Market, by Brand, France, (US$), 2003-2009
Exhibit 4-17: Moderate to Severe AD Drug Market, by Brand, France, (€), 2003-2009
Exhibit 4-18: Moderate to Severe AD Drug Market, by Brand, Germany, (US$), 2003-2009
Exhibit 4-19: Moderate to Severe AD Drug Market, by Brand, Germany, (€), 2003-2009
Exhibit 4-20: Moderate to Severe AD Drug Market, by Brand, UK, (US$), 2003-2009
Exhibit 4-21: Moderate to Severe AD Drug Market, by Brand, UK, (€), 2003-2009
Exhibit 4-22: Moderate to Severe AD Drug Market, by Brand, UK, (£), 2003-2009
Exhibit 4-23: Moderate to Severe AD Drug Market, by Brand, Italy, (US$), 2003-2009
Exhibit 4-24: Moderate to Severe AD Drug Market, by Brand, Italy, (€), 2003-2009
Exhibit 4-25: Moderate to Severe AD Drug Market, by Brand, Spain, (US$), 2003-2009
Exhibit 4-26: Moderate to Severe AD Drug Market, by Brand, Spain, (€), 2003-2009
Exhibit 4-27: Moderate to Severe AD Drug Market, by Brand, Japan, (US$), 2003-2009 (Tabular Format)
Exhibit 4-28: Moderate to Severe AD Drug Market, by Brand, Japan, (¥), 2003-2009
Exhibit 4-29: Moderate to Severe AD Drug Market, by Brand, Japan, (US$), 2003-2009 (Graphical Format)
Exhibit 4-30: Leading Competitors in the Moderate to Severe AD Drug Market, by Region, Global, 2004
Exhibit 4-31: Exhibit 4-24: Leading Competitors in the Moderate to Severe AD Drug Market, by Region, Europe, 2004
Exhibit 4-32: Leading Competitors in the Moderate to Severe AD Drug Market, Global, 2004
CHAPTER 5: RESEARCH AND DEVELOPMENT
Exhibit 5-1: Selected New AD Drug Candidates, by Clinical Stage, Q4 2004
Exhibit 5-2: Selected ACh Modulators Drug Candidates, by Clinical Stage, Q4 2004
Exhibit 5-3: Selected Neuroprotective and Neurotrophic Drug Candidates, by Clinical Stage, Q4 2004
Exhibit 5-4: Selected Beta Amyloid Modulators Drug Candidates, by Clinical Stage, Q4 2004
Exhibit 5-5: Selected BACE Inhibitor Drug Candidates, by Clinical Stage, Q4 2004

Abstract

The global AD drug market will continue to experience strong growth over the forecast period driven by increasing AD prevalence, physician and patient awareness, improved diagnostic tools, increasing prices, the introduction of new AD products, and expanded indications for existing products.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

advertise with us

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Global Markets for Alzheimer's Disease Medications

Table of Contents

Abstract